Possible endocannabinoid control of colorectal cancer growth

Gastroenterology

Volumn 125, Issue 3, 2003, Pages 677-687

  Ligresti, Alessia ^a   Bisogno, Tiziana ^a   Matias, Isabel ^a   De Petrocellis, Luciano ^a   Cascio, Maria Grazia ^a   Cosenza, Vittorio ^b   D'Argenio, Giuseppe ^b   Scaglione, Giuseppe ^c   Bifulco, Maurizio ^d   Sorrentini, Italo ^c   Di Marzo, Vincenzo ^a  

^a CNR   (Italy)

^b UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^c Gastroenterologia   (Italy)

^d UNIVERSITY OF SALERNO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

2 ARACHIDONOYLGLYCEROL; 5 (4 CHLORO 3 METHYLPHENYL) 1 (4 METHYLBENZYL) N (1,3,3 TRIMETHYLBICYCLO[2.2.1]HEPTAN 2 YL) 3 PYRAZOLECARBOXAMIDE; ANANDAMIDE; ARACHIDONOYLCHLOROANANDAMIDE; CANNABINOID; CANNABINOID 1 RECEPTOR; CANNABINOID 2 RECEPTOR; CANNABINOID RECEPTOR; CANNABINOID RECEPTOR AGONIST; CYCLOOXYGENASE 2 INHIBITOR; DEXANABINOL; ENDOCANNABINOID; FATTY ACID AMIDASE; INDOMETACIN; N ARACHIDONOYLDOPAMINE; RIMONABANT; UNCLASSIFIED DRUG;

ADENOMATOUS POLYP; ARTICLE; CANCER GROWTH; CELL PROLIFERATION; CELL STRAIN CACO 2; COLONOSCOPY; COLORECTAL CANCER; CONTROLLED STUDY; HUMAN; HUMAN CELL; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

EID: 0042972716     PISSN: 00165085     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0016-5085(03)00881-3     Document Type: Article

References (36)

1. De Petrocellis L, Melck D, Bisogno T, Di Marzo V. Endocannabinoids and fatty acid amides in cancer, inflammation and related disorders. Chem Phys Lipids 2000;108:191-209.
2. Bifulco M, Di Marzo V. Targeting the endocannabinoid system in cancer therapy: a call for further research. Nat Med 2002;8:547-550.
3. Gaoni Y, Mechoulam R. Isolation, structure and partial synthesis of an active constituent of hashish. J Am Chem Soc 1964;86:1646-1656.
4. Pertwee RG. Pharmacology of cannabinoid CB1 and CB2 receptors. Pharmacol Ther 1997;74:129-180.
5. Munson AE, Harris LS, Friedman MA, Dewey WL, Carchman RA. Antineoplastic activity of cannabinoids. J Natl Cancer Inst 1975;55:597-602.
6. Galve-Roperh I, Sanchez C, Cortes ML, del Pulgar TG, Izquierdo M, Guzman M. Anti-tumoral action of cannabinoids: involvement of sustained ceramide accumulation and extracellular signal-regulated kinase activation. Nat Med 2000;6:313-319.
7. Devane WA, Hanus L, Breuer A, Pertwee RG, Sevenson LA, Griffin G, Gibson D, Mandelbaum A, Etinger A, Mechoulam R, Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 1992;258:1946-1949.
8. Mechoulam R, Ben-Shabat S, Hanus L, Ligunsky M, Kaninski NE, Schatz AR, Gopher A, Almog S, Martin BR, Compton DR, Pertwee RG, Griffin G, Bayewitch M, Barg J, Vogel Z. Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinnoid receptors. Biochem Pharmacol 1995;50:83-90.
9. Sugiura T, Kondo S, Sukagawa A, Nakane S, Shinoda A, Itoh K, Yamashita A, Waku K. 2-arachidonoylglycerol: a possible endogenous cannabinoid receptor ligand in brain. Biochem Biophys Res Commun 1995;215:89-97.
10. Hanus L, Abu-Lafi S, Fride E, Breuer A, Vogel Z, Shalev DE, Kustanovich I, Mechoulam R. 2-Arachidonyl glyceryl ether, an endogenous agonist of the cannabinoid CB1 receptor. Proc Natl Acad Sci U S A 2001;98:3662-3665.
11. De Petrocellis L, Melck D, Palmisano A, Bisogno T, Laezza C, Bifulco M, Di Marzo V. The endogenous cannabinoid anandamide inhibits human breast cancer cell proliferation. Proc Natl Acad Sci U S A 1998;95:8375-8380.
12. Melck D, De Petrocellis L, Orlando P, Bisogno T, Laezza C, Bifulco M, Di Marzo V. Suppression of nerve growth factor Trk receptors and prolactin receptors by endocannabinoids leads to inhibition of human breast and prostate cancer cell proliferation. Endocrinology 2000;141:118-126.
13. Bifulco M, Laezza C, Portella G, Vitale M, Orlando P, De Petrocellis L, Di Marzo V. Control by the endogenous cannabinoid system of ras oncogene-dependent tumor growth. FASEB J 2001;15:2745-2747.
14. Guzman M, Sanchez C, Galve-Roperh I. Control of the cell survival/death decision by cannabinoids. J Mol Med 2001;78:613-625.
15. Dempke W, Rie C, Grothey A, Schmoll HJ. Cyclooxygenase-2: a novel target for cancer chemotherapy? J Cancer Res Clin Oncol 2001;127:411-417.
16. Marnett LJ. Recent developments in cyclooxygenase inhibition. Prostaglandins Other Lipid Mediat 2002;68-69:153-164.
17. Nakane S, Oka S, Arai S, Waku K, Ishima Y, Tokumura A, Sugiura T. Arachidonoyl-sn-glycero-3-phosphate, an arachidonic acid-containing lysophosphatidic acid: occurrence and rapid enzymatic conversion to 2-arachidonoyl-sn-glycerol, a cannabinoid receptor ligand, in rat brain. Arch Biochem Biophys 2002;402:51-58.
18. Huang MC, Graeler M, Shankar G, Spencer J, Goetzl EJ. Lysophospholipid mediators of immunity and neoplasia. Biochim Biophys Acta 2002;1582:161-167.
19. Merchant TE, Kasimos JN, de Graaf PW, Minsky BD, Guerke LW, Glonek T. Phospholipid profiles of human colon cancer using 31P magnetic resonance spectroscopy. Int J Colorectal Dis 1991;6:121-126.
20. Smith G, Carey FA, Beattie J, Wilkie MJ, Lightfoot TJ, Coxhead J, Garner RC, Steele RJ, Wolf CR. Mutations in APC, Kirsten-ras, and p53 - alternative genetic pathways to colorectal cancer. Proc Natl Acad Sci U S A 2002;99:9433-9438.
21. De Petrocellis L, Bisogno T, Davis JB, Pertwee RG, Di Marzo V. Overlap between the ligand recognition properties of the anandamide transporter and the VR1 vanilloid receptor: inhibitors of anandamide uptake with negligible capsaicin-like activity. FEBS Lett 2000;483:52-56.
22. Dahlquist A. Method of assay of intestinal disaccharidases. Anal Biochem 1964;7:18-25.
23. Marsicano G, Wotjak CT, Azad SC, Bisogno T, Rammes G, Cascio MG, Hermann H, Tang J, Hofmann C, Zieglgansberger W, Di Marzo V, Lutz B. The endogenous cannabinoid system controls extinction of aversive memories. Nature 2002;418:530-534.
24. Izzo AA, Fezza F, Capasso R, Bisogno T, Pinto L, Iuvone T, Esposito G, Mascolo N, Di Marzo V, Capasso F. Cannabinoid CB1-receptor mediated regulation of gastrointestinal motility in mice in a model of intestinal inflammation. Br J Pharmacol 2001;134:563-570.
25. Katayama K, Ueda N, Kurahashi Y, Suzuki H, Yamamoto S, Kato I. Distribution of anandamide amidohydrolase in rat tissues with special reference to small intestine. Biochim Biophys Acta 1997;1347:212-218.
26. Kennedy BP, Soravia C, Moffat J, Xia L, Hiruki T, Collins S, Gallinger S, Bapat B. Overexpression of the nonpancreatic secretory group II PLA2 messenger RNA and protein in colorectal adenomas from familial adenomatous polyposis patients. Cancer Res 1998;58:500-503.
27. Di Popolo A, Memoli A, Apicella A, Tuccillo C, di Palma A, Ricchi P, Acquaviva AM, Zarrilli R. IGF-II/IGF-I receptor pathway up-regulates COX-2 mRNA expression and PGE2 synthesis in Caco-2 human colon carcinoma cells. Oncogene 2000;19:5517-5524.
28. Huang SM, Bisogno T, Trevisani M, Al-Hayani A, De Petrocellis L, Fezza F, Tognetto M, Petros TJ, Krey JF, Chu CJ, Miller JD, Davies SN, Geppetti P, Walker JM, Di Marzo V. An endogenous capsaicin-like substance with high potency at recombinant and native vanilloid VR1 receptors. Proc Natl Acad Sci U S A 2002;99:8400-8405.
29. Di Marzo V, De Petrocellis L, Bisogno T. Endocannabinoids 1. Molecular basis of endocannabinoid formation, action and inactivation, and development of selective inhibitors. Emerg Ther Targets 2001;5:241-266.
30. Bisogno T, Melck D, De Petrocellis L, Bobrov MY, Gretskaya NM, Bezuglov VV, Sitachitta N, Gerwick WH, Di Marzo V. Arachidonoyl-serotonin and other novel inhibitors of fatty acid amide hydrolase. Biochem Biophys Res Commun 1998;248:515-522.
31. Tsujii M, Kawano S, DuBois RN. Cyclooxygenase-2 expression in human colon cancer cells increases metastatic potential. Proc Natl Acad Sci U S A 1997;94:3336-3340.
32. Steinert M, Wobus M, Boltze C, Schutz A, Wahlbuhl M, Hamann J, Aust G. Expression and regulation of CD97 in colorectal carcinoma cell lines and tumor tissues. Am J Pathol 2002;161:1657-1667.
33. Jessani N, Liu Y, Humphrey M, Cravatt BF. Enzyme activity profiles of the secreted and membrane proteome that depict cancer cell invasiveness. Proc Natl Acad Sci U S A 2002;99:10335-10340.
34. Tsuji S, Kawano S, Sawaoka H, Takei Y, Kobayashi I, Nagano K, Fusamoto H, Kamada T. Evidences for involvement of cyclooxygenase-2 in proliferation of two gastrointestinal cancer cell lines. Prostaglandins Leukot Essent Fatty Acids 1996;55:179-183.
35. Kalgutkar AS, Crews BC, Rowlinson SW, Marnett AB, Kozak KR, Remmel RP, Marnett LJ. Biochemically based design of cyclooxygenase-2 (COX-2) inhibitors: facile conversion of nonsteroidal antiinflammatory drugs to potent and highly selective COX-2 inhibitors. Proc Natl Acad Sci U S A 2000;97:925-930.
36. Schmid PC, Wold LE, Krebsbach RJ, Berdyshev EV, Schmid HH. Anandamide and other N-acylethanolamines in human tumors. Lipids 2002;37:907-912.